Oncology Diagnostics

News and new technology innovations for oncology diagnostics can be found on this channel.

contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016

September 12, 2016 — Tiny microbubbles are being used to more effectively...

Guided Therapeutics, LuViva Advanced Cerivcal Scan, first to Russia, cervical cancer
News | Oncology Diagnostics | August 24, 2016

August 24, 2016 — Guided Therapeutics Inc. announced in late July that it has sold the first LuViva Advanced...

LiverMultiScan, liver disease diagnosis, children, pediatric patients, U.K., Poland, Kids4LIFe consortium
News | Oncology Diagnostics | July 27, 2016

July 27, 2016 — A U.K-Poland consortium was recently awarded a €1.1M grant to develop a...

News | Oncology Diagnostics | July 27, 2016

July 27, 2016 — Cubresa Inc. announced the United States Patent and Trademark Office has issued a U.S. patent for a...

metastatic prostate cancer incidence, Northwestern Medicine study, Edward Schaeffer, Adam Weiner
Feature | Prostate Cancer | July 25, 2016

July 25, 2016 — The number of new cases of metastatic...

PET-CT, advanced cancer, lean body mass, LBM, SNMMI 2016 study
News | Oncology Diagnostics | June 23, 2016

June 23, 2016 — Cancer patients often experience significant fluctuations in weight and lean body mass (LBM)....

blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016

June 23, 2016 — Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and...

News | Oncology Diagnostics | May 25, 2016

May 25, 2016 — Scientists are developing a new photonics device that listens to light and could be capable of...

News | Oncology Diagnostics | May 25, 2016

May 25, 2016 — Researchers at Haukeland University Hospital in Bergen, Norway, have combined a laboratory...

patient data sharing, cancer treatment, Queen's University Belfast
News | Oncology Diagnostics | May 18, 2016

May 18, 2016 — The sharing of genetic information from millions of cancer patients around the world could be key to...

cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell

Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat...

News | Radiopharmaceuticals and Tracers | May 09, 2016

May 9, 2016 — A recent study demonstrates that Ga-68 DOTATATE...

News | Oncology Diagnostics | May 06, 2016

May 6, 2016 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus...

Carestream, oncology workflow, PET/CT, Vue Motion
Technology | Oncology Diagnostics | May 05, 2016

May 5, 2016 — Carestream now offers an oncology reading workflow for...

Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016

April 20, 2016 — Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical...

cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016

March 31, 2016 — In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current...

Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

News | Oncology Related Products | March 15, 2016

March 15, 2016 — Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical...